Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
Matthew S. Davids(Harvard University), Andrew W. Roberts(The Royal Melbourne Hospital), Lori A. Gressick(AbbVie (United States)), Sari H. Enschede(AbbVie (United States)), Nikita Rudersdorf(AbbVie (United States)), Nicholas P. Montalvo(AbbVie (United States)), John M. Pagel(University of Washington), Rod Humerickhouse(Abbott Fund), Brad S. Kahl(UW Health University Hospital), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), John F. Seymour(The Royal Melbourne Hospital), Ming Zhu(AbbVie (United States)), William G. Wierda(University of Maryland, Baltimore), Mary Ann Anderson(The Royal Melbourne Hospital), Elisa Cerri(AbbVie (United States)), Jianning Yang(AbbVie (United States)), Martin Dunbar(AbbVie (United States))
Cited by 91
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k